Orudis (Ketoprofen)

Ketoprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin synthesis. By lowering prostaglandin levels, it diminishes inflammation, pain signaling, and fever, providing therapeutic relief in inflammatory conditions.

The dosage of Orudis is individualized by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. The prescriber determines the appropriate strength, frequency, and duration of therapy to achieve optimal therapeutic effect while minimizing risk.

Ketoprofen is generally avoided in the third trimester of pregnancy because it may affect fetal cardiovascular function. Use during earlier stages should be considered only if the potential benefit outweighs the risk. It is excreted in breast milk, so nursing mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Orudis. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Ketoprofen, the active ingredient in Orudis, has a longer half‑life and may provide more sustained analgesia than ibuprofen, allowing for less frequent dosing in some patients. Both share similar mechanisms and risk profiles, but ketoprofen can be more potent in reducing inflammation, while ibuprofen is often preferred for its broader safety data in over‑the‑counter use.

Orudis tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments to maintain stability and potency.

Orudis is administered orally, typically with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal irritation. The exact dosing schedule is determined by the prescribing clinician based on therapeutic needs.

The most serious risks include gastrointestinal ulceration or bleeding, severe renal impairment, hepatotoxicity, cardiovascular events such as myocardial infarction or stroke, and life‑threatening hypersensitivity reactions like anaphylaxis. Patients should be monitored for signs of these conditions and discontinue use if they occur.

Orudis should not be used by individuals with known hypersensitivity to ketoprofen or other NSAIDs, patients with active gastrointestinal bleeding or ulcer disease, those in the third trimester of pregnancy, and patients with severe renal or hepatic insufficiency unless specifically directed by a physician.